India's Marksans Pharma rises as unit gets nod to market diarrhoea medicine in UK

Marksans Pharma

10/12/2021 05:50

** Shares of pharmaceutical co  MARK.NS  rise as much as
7.6% to 64.45 rupees, their highest since Nov. 10
    ** Stock posts biggest intraday pct gain since Oct. 4, up
for a second straight session
    ** MARK said https://bit.ly/3pL5kcA on Thursday UK's
Medicines and Healthcare products Regulatory Agency (MHRA) has
granted market authorisation to co's unit for diarrhoea medicine
Loperamide
    ** Co said it would make the product at its UK MHRA-approved
facility in Goa 
    ** More than 3.7 mln shares traded by 0530 GMT, 2 times
their 30-day avg of over 1.7 mln shares 
    ** As of last close, MARK stock had fallen 1.2% this year vs
a 4.13% gain in the Nifty Pharma index  .NIPHARM  

 (Reporting by Rama Venkat in Bengaluru)
 ((ramavenkat.raman@thomsonreuters.com; https://twitter.com/ramavenkat0607;))